SynAct Pharma AB (publ) (“SynAct”) today announced that the protocol amendment of the ongoing SynAct-CS003 study with the Company’s candidate drug AP1189 in idiopathic membranous nephropathy (iMN) patients with severe proteinuria and/or Nephrotic Syndrome (NS) has been approved.
On 28 March 2022, SynAct Pharma AB (“SynAct” or the “Company”) announced that the board of directors had resolved on a preferential rights issue of approximately SEK 150 million (the “Rights Issue”). The subscription period of the Rights Issue ended on 22 April 2022. Today, SynAct announces the outcome of the Rights Issue. The subscription summary shows that 1,252,033 shares, corresponding to 53 percent of the Rights Issue, were subscribed for with and without subscription rights. Accordingly, the guarantors are allocated approximately 47 percent of the Rights Issue, whereby the Rights Issue is subscribed to 100 percent. The Company will receive total proceeds of approximately SEK 150 million before transaction costs.